Modulation of early non-rapid eye movement slow wave activity by ketamine in treatment-resistant depression.
Nadia Hejazi, Mina Kheirkhah, Brady Riedner et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial investigated the effects of ketamine on non-rapid eye movement (NREM1) slow wave activity (SWA) in 91 unmedicated patients with treatment-resistant depression (TRD) compared to 42 healthy volunteers. Ketamine significantly increased NREM1 SWA in TRD patients, particularly among responders, while having no effect in healthy volunteers. At baseline, TRD patients exhibited lower NREM1 SWA than healthy volunteers.
Key findings
- Ketamine increased NREM1 SWA in TRD patients, while placebo did not.
- TRD patients had lower NREM1 SWA at baseline compared to healthy volunteers.
- Following ketamine, TRD patients showed increased total sleep time and sleep efficiency.
- The increase in NREM1 SWA diminished with increasing age in TRD patients.
Why it matters
Understanding how ketamine modulates sleep architecture and SWA in treatment-resistant depression can inform treatment strategies and improve patient outcomes. Enhanced sleep quality may contribute to the overall antidepressant effects of ketamine.